Biomerica Inc (BMRA) Return on Investment ROI from the fourth quarter of 2026 to fourth quarter of 2025 and for the year 2026, average high and low, overall ranking from May 31 2026 to May 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Biomerica Inc   (NASDAQ: BMRA)


Biomerica Inc's ROI from its fourth quarter of 2026 to the fourth quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Biomerica Inc's ROI in the fourth quarter of 2026?
Biomerica Inc recorded a cumulative net loss of $-4 million during 12 months ending in the fourth quarter of 2026, resulting in a negative return on investment (ROI) of -89.03%.

Within the Healthcare sector 197 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2026 from 3689 to 3980.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (May 31 2026)
IV. Quarter		 (Feb 28 2026)
III. Quarter		 (Nov 30 2025)
II. Quarter		 (Aug 31 2025)
I. Quarter		 (May 31 2025)
IV. Quarter
Y / Y Investment Change TTM -25.29 % -33.89 % -31.49 % -34.16 % -42.36 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 4 3 4 5 4
Return On Investment (TTM) -89.03 % -98.86 % -83.43 % -66.03 % -87.63 %
BMRA's Overall Ranking # 3980 # 3689 # 3486 # 1237 # 3454
Seq. Investment Change TTM 0.43 % -12.49 % -12.85 % -2.46 % -11.14 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -4 -4 -4 -4 -5

BMRA Company Profile >> Back to BMRA Roi Comparisons >> See Annual BMRA Return On Investment



Return On Investment BMRA's Ranking
Within: No.
Industry # 4
Sector # 198
Overall # 3980

Return On Investment Statistics
High Average Low
15.92 %
-50.85 %
-98.86 %
(May 31 2017)   (Feb 28 2026)



  News about Biomerica Inc Return on Investment ROI

Biomerica Defies Odds in Expanding inFoods IBS Platform, Poised to Revolutionize Healthcare

April 15, 2024



In an era of increasing public health concerns and escalating medical expenses, Biomerica, a leading global provider of advanced diagnostic products, is making groundbreaking strides in expanding its innovative inFoods platform dedicated to managing and treating Irritable Bowel Syndrome (IBS). With a mission to transform healthcare outcomes for millions of individuals suffering from this common but debilitating condition, Biomerica is now unveiling a major expansion plan that includes the establishment of new offices within existing leading medical groups in the Northeast, Ohio, and Texas.
IBS, often characterized by abdominal pain, bloating, and changes in bowel habits, is estimated to affect over 25 million people in the United States alone. Traditional diagnostic approaches for IBS have been riddled with uncertainties, resulting in inaccurate diagnoses and misguided treatment plans. However, Biomerica s inFoods platform offers a beacon of hope through its revolutionary precision medicine approach.

Gary Huff's Appointment to Biomerica Strategic Advisory Board Signals Promising Future Amidst Challenging Market Conditions

February 21, 2024



Biomerica Inc, a leading player in the diagnostics industry, recently welcomed Gary Huff, the former CEO of LabCorp Diagnostics, to its Strategic Advisory Board. The appointment of Mr. Huff, a seasoned executive with extensive experience in medical diagnostics and healthcare, comes at a critical time as the company strives to navigate a difficult first quarter in 2024.
During this challenging period, Biomerica Inc saw its share price decline by -15.87%, highlighting the testing market s volatility and the adversity faced by many companies in the healthcare sector. Furthermore, the company recorded a cumulative net loss of $-6 million in the second quarter of 2024, resulting in a negative return on investment (ROI) of -59.61%. These figures underscore the significant challenges Biomerica Inc is currently grappling with.





Financial Statements
Biomerica Inc's IV. Quarter Investments $ 4 Millions BMRA's Balance sheet
Biomerica Inc's IV. Quarter Income $ -1 Millions Quarterly BMRA's Income Statement
BMRA's Income by Division See BMRA's Income by Division


BMRA Annual Return On Investment (May 31 2026)
2026		 (May 31 2025)
2025		 (May 31 2024)
2024		 (May 31 2023)
2023		 (May 31 2022)
2022
Total Investments in Millions 4 4 7 13 9
Y / Y Investment Growth 1.74 % -40.35 % -43.64 % 33.6 % -10.99 %
Net Income in Millions -4 -5 -6 -7 -5
Y / Y Net Income Growth - - - - -
Annual Return On Investment -88.24 % -118.26 % -84.79 % -57.08 % -48.39 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
In Vitro & In Vivo Diagnostic Substances Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
BMRA's Roi Ratio versus In Vitro & In Vivo Diagnostic Substances Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for BMRA's Competitors
Subscribers only: Roi for Biomerica Inc's Suppliers
Subscribers only: Return On Investment for BMRA's Customers

Other Ratios
BMRA's Roa BMRA's Inventory Turnover Ratio BMRA's Growth Rates BMRA's Dividend Statistics
BMRA's Profitability Ratios BMRA's Asset Turnover Ratio BMRA's Dividend Growth
BMRA's Roe BMRA's Valuation Ratios BMRA's Financial Strength Ratios BMRA's Dividend Payout Ratio



Companies with similar Return On Investment at May 31 2026, within Healthcare Sector ROI

Date modified: 2026-09-05T08:34:47+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.